sky business news - income from trials

ABIX Summary
Australian artificial heart maker, Ventracor, expects to generate revenue in 2004-05. The company hopes to gain approval for trials in the US, which would begin in early 2005. The US Government has indicated that the company will be able to charge between $US125,000 ($A170,000) and $US130,000 for each device used in the trials. Ventracor is already undertaking trials in order to gain European approval. It could possibly also gain income from these trials. The company expects to have a significant cash flow in 2005-06